Trends In Insulin Therapy Acceptance In India
This article was originally published in Scrip
Executive Summary
An eight-city physician survey in India has thrown up some interesting findings on diabetes treatment approaches in the country, including that a significant percentage of physicians shift patients managed on oral therapies to insulin within three years largely because of poor glycemic control.
You may also be interested in...
Can Sanofi’s Toujeo Prickle Tresiba In India?
Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.